linsidomine has been researched along with Idiopathic Parkinson Disease in 5 studies
linsidomine: RN given refers to parent cpd; structure
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)." | 7.73 | Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006) |
| "We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)." | 3.73 | Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hung, LW | 1 |
| Villemagne, VL | 1 |
| Cheng, L | 1 |
| Sherratt, NA | 1 |
| Ayton, S | 1 |
| White, AR | 1 |
| Crouch, PJ | 1 |
| Lim, S | 1 |
| Leong, SL | 1 |
| Wilkins, S | 1 |
| George, J | 1 |
| Roberts, BR | 1 |
| Pham, CL | 1 |
| Liu, X | 1 |
| Chiu, FC | 1 |
| Shackleford, DM | 1 |
| Powell, AK | 1 |
| Masters, CL | 1 |
| Bush, AI | 1 |
| O'Keefe, G | 1 |
| Culvenor, JG | 1 |
| Cappai, R | 1 |
| Cherny, RA | 1 |
| Donnelly, PS | 1 |
| Hill, AF | 1 |
| Finkelstein, DI | 1 |
| Barnham, KJ | 1 |
| Lev, N | 1 |
| Melamed, E | 1 |
| Offen, D | 1 |
| Jiang, H | 1 |
| Wu, YC | 1 |
| Nakamura, M | 1 |
| Liang, Y | 1 |
| Tanaka, Y | 1 |
| Holmes, S | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Ross, CA | 1 |
| Smith, WW | 1 |
| Ebadi, M | 1 |
| Sharma, S | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
5 other studies available for linsidomine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Cognition; Coordination Complexes; Disease Models, Anima | 2012 |
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Topics: alpha-Synuclein; Benzothiazoles; Cell Differentiation; Cell Line, Tumor; Cytoplasm; Ferrous Compound | 2006 |
Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Topics: alpha-Synuclein; Animals; Cell Death; Dose-Response Relationship, Drug; Genetic Predisposition to Di | 2007 |
Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Coenzymes; Dopamine; Enzyme Activation; Lipid Peroxidation; | 2006 |
Future of neuroprotection in Parkinson's disease.
Topics: Apoptosis; Humans; Molsidomine; Neuroprotective Agents; Neurotoxins; Nitric Oxide Donors; Oxidopamin | 2001 |